Recommended Treatment for Onychomycosis
For adults with dermatophyte onychomycosis, offer oral terbinafine as first-line systemic therapy (250 mg daily for 6 weeks for fingernails or 12 weeks for toenails), and combine with topical amorolfine nail lacquer for optimal outcomes, particularly when multiple nails are affected or the nail matrix is involved 1.
Treatment Algorithm Based on Disease Severity
Mild to Moderate Disease (Superficial/Distal Involvement)
- Topical monotherapy with amorolfine nail lacquer is appropriate when nail involvement is limited and the matrix is not affected 1
- Efinaconazole 10% topical is also highly effective for topical treatment 2, 3
- Consider topical therapy when less than 20% of the nail is involved 3
Moderate to Severe Disease (Multiple Nails or Matrix Involvement)
- Oral terbinafine is the primary systemic choice 1, 2
- Dosing: 250 mg daily for 6 weeks (fingernails) or 12 weeks (toenails)
- Superior efficacy compared to azoles
- Combination therapy (oral + topical) is recommended for better outcomes 1, 4
- Alternative systemic options if terbinafine is contraindicated:
Special Populations
Patients with Diabetes
- Offer terbinafine as first-line for dermatophyte infection 1
- Assess risk of foot infections and ulcers on a case-by-case basis before deciding treatment intensity 1
- Consider azoles for non-dermatophyte mould or Candida infections (avoid if congestive heart failure present) 1
Immunosuppressed Patients
- Offer terbinafine or fluconazole preferentially 1
- Avoid itraconazole due to higher risk of drug interactions, particularly with antiretroviral therapy 1
- Consider amorolfine nail lacquer when systemic treatments are contraindicated or not tolerated 1
Children and Young People
- Consider amorolfine nail lacquer for superficial/distal infection 1
- Do not offer griseofulvin despite being the only licensed systemic agent—it has long treatment duration and low efficacy 1
- For multiple nails or matrix involvement, consider off-label systemic therapy with weight-based dosing:
Older Adults (>70 years)
- Insufficient evidence exists to specify ideal agents, but general adult recommendations apply with attention to comorbidities and drug interactions 1
Critical Diagnostic Requirement
Always confirm diagnosis with mycological testing (microscopy, culture, and/or molecular testing) before initiating treatment 4, 5, 6. Approximately half of nail dystrophies are non-fungal, making confirmation essential to avoid unnecessary antifungal use 6.
Monitoring and Follow-up
- Consider therapeutic drug monitoring for itraconazole if compliance is questionable 1
- Consider blood-test monitoring when concerns exist regarding:
- Comorbidities
- Drug-drug interactions
- Long treatment duration 1
Preventing Recurrence
- Replace or sanitize contaminated footwear 1
- Apply topical antifungal shoe sprays to insoles weekly or twice monthly after complete cure 1
- Treat concomitant tinea pedis promptly 1
- Consider off-label efinaconazole for maintenance therapy to prevent recurrence 2
Common Pitfalls to Avoid
- Do not start treatment without mycological confirmation—clinical appearance alone is insufficient 6
- Do not use griseofulvin in children despite its licensing status 1
- Avoid itraconazole in immunosuppressed patients on antiretroviral therapy due to interaction risk 1
- Do not undertreat—ensure adequate treatment duration as nail growth takes 12-18 months for toenails 2
- Counsel patients on realistic expectations—treatment success requires adherence and proper follow-up 2